CU24042B1 - Método para la inducción de diferenciación de células madre mesenquimales - Google Patents
Método para la inducción de diferenciación de células madre mesenquimalesInfo
- Publication number
- CU24042B1 CU24042B1 CU2012000007A CU20120007A CU24042B1 CU 24042 B1 CU24042 B1 CU 24042B1 CU 2012000007 A CU2012000007 A CU 2012000007A CU 20120007 A CU20120007 A CU 20120007A CU 24042 B1 CU24042 B1 CU 24042B1
- Authority
- CU
- Cuba
- Prior art keywords
- differentiation
- induction
- mesenquimal
- stem cells
- mother cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención proporciona métodos para la inducción de la diferenciación de células madre mesenquimales en condrocitos, los cuales forman la matriz del cartílago, al poner en contacto células madre mesenquimales con un polipéptido específico. Adicionalmente, la presente invención proporciona composiciones farmacéuticas para la administración intramuscular y sistémica, que comprenden una cantidad farmacéuticamente efectiva del polipéptido que induce la diferenciación de las células madres en condrocitos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22529309P | 2009-07-14 | 2009-07-14 | |
PCT/US2010/041850 WO2011008773A2 (en) | 2009-07-14 | 2010-07-13 | Mesenchymal stem cell differentiation |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20120007A7 CU20120007A7 (es) | 2013-02-26 |
CU24042B1 true CU24042B1 (es) | 2014-11-27 |
Family
ID=43450138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2012000007A CU24042B1 (es) | 2009-07-14 | 2012-01-16 | Método para la inducción de diferenciación de células madre mesenquimales |
Country Status (31)
Country | Link |
---|---|
US (4) | US9139633B2 (es) |
EP (1) | EP2453921B1 (es) |
JP (1) | JP5602850B2 (es) |
KR (3) | KR20160015403A (es) |
CN (2) | CN105601728B (es) |
AU (1) | AU2010273570B2 (es) |
BR (1) | BR112012000914B8 (es) |
CA (1) | CA2767826C (es) |
CL (1) | CL2012000091A1 (es) |
CO (1) | CO6491059A2 (es) |
CR (1) | CR20120024A (es) |
CU (1) | CU24042B1 (es) |
EA (1) | EA023073B1 (es) |
EC (1) | ECSP12011604A (es) |
ES (1) | ES2541217T3 (es) |
GT (1) | GT201200011A (es) |
HK (1) | HK1164169A1 (es) |
IL (2) | IL217383A (es) |
IN (1) | IN2012DN00572A (es) |
MA (1) | MA33423B1 (es) |
MX (1) | MX2012000707A (es) |
MY (1) | MY160951A (es) |
NZ (1) | NZ597306A (es) |
PE (2) | PE20120570A1 (es) |
PL (1) | PL2453921T3 (es) |
PT (1) | PT2453921E (es) |
SG (1) | SG177318A1 (es) |
TN (1) | TN2011000655A1 (es) |
UA (1) | UA104031C2 (es) |
WO (1) | WO2011008773A2 (es) |
ZA (1) | ZA201200078B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160015403A (ko) * | 2009-07-14 | 2016-02-12 | 더 스크립스 리서치 인스티튜트 | 중간엽 줄기 세포 분화 |
JO3412B1 (ar) | 2011-06-17 | 2019-10-20 | Regeneron Pharma | أجسام مضادة ل angptl3 واستخداماتها |
CN110446037B (zh) | 2011-11-08 | 2022-01-04 | 韩国电子通信研究院 | 用于共享候选者列表的方法和装置 |
US9790264B2 (en) | 2012-06-25 | 2017-10-17 | The Brigham And Women's Hospital, Inc. | Compounds and methods for modulating pharmacokinetics |
HUE035607T2 (en) * | 2012-06-25 | 2018-05-28 | Brigham & Womens Hospital Inc | Targeted therapeutic agents |
MA38369B1 (fr) | 2013-03-08 | 2018-10-31 | Novartis Ag | Peptides et compositions pour le traitement d'une lesion de l'articulation |
UY35368A (es) * | 2013-03-08 | 2014-10-31 | Irm Llc | Péptidos y composiciones para el tratamiento de daño articular |
ES2900815T3 (es) | 2013-03-15 | 2022-03-18 | Scripps Research Inst | Compuestos y métodos para inducir la condrogénesis |
BR112016025659B1 (pt) | 2014-05-13 | 2023-03-07 | Novartis Ag | Indutores de condrogênese, seu uso, e composição farmacêutica |
CN104840486A (zh) * | 2015-04-30 | 2015-08-19 | 北京益诺勤生物技术有限公司 | 一种组合物及其应用、制剂 |
KR20190084287A (ko) * | 2016-11-14 | 2019-07-16 | 노파르티스 아게 | 연골 손상 및 관절염 치료 방법 및 조성물 |
JOP20190282A1 (ar) | 2017-06-09 | 2019-12-05 | Novartis Ag | مركبات وتركيبات لحث تكوّن الغضاريف |
TW202027794A (zh) | 2018-10-03 | 2020-08-01 | 瑞士商諾華公司 | 血管生成素樣3多肽之持續遞送 |
EP3891154B1 (en) | 2018-12-06 | 2023-08-16 | Novartis AG | 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage |
ES2965684T3 (es) * | 2018-12-06 | 2024-04-16 | Novartis Ag | Derivados de 6-hidroxi-8-oxatriciclo[3.2.1.02,4]octano-2-carboxamida para inducir condrogénesis para el tratamiento del daño articular |
CN109432128A (zh) * | 2018-12-07 | 2019-03-08 | 卡替(上海)生物技术股份有限公司 | 牙髓间充质干细胞在银屑病治疗中的应用 |
KR102246582B1 (ko) * | 2019-04-03 | 2021-04-30 | 이화여자대학교 산학협력단 | 올리고펩타이드를 이용한 줄기세포의 연골세포로의 분화 유도 방법 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5462990A (en) * | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
US5972338A (en) * | 1997-09-19 | 1999-10-26 | Genentech, Inc. | Tie ligands homologues |
WO1999055869A1 (en) | 1998-04-27 | 1999-11-04 | Zymogenetics, Inc. | Novel polypeptide growth factors and materials and methods for making them |
EP1078046A4 (en) * | 1998-05-12 | 2005-05-11 | Human Genome Sciences Inc | 97 HUMAN SECRETED PROTEINS |
WO1999067382A2 (en) * | 1998-06-24 | 1999-12-29 | Compugen Ltd. | Angiopoietin-like growth factor sequences |
AU768694B2 (en) | 1999-03-08 | 2004-01-08 | Genentech Inc. | Promotion or inhibition of angiogenesis and cardiovascularization |
CA2375458A1 (en) | 1999-07-20 | 2001-01-25 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US20030013649A1 (en) * | 2000-01-31 | 2003-01-16 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
US20030144498A1 (en) * | 2000-10-16 | 2003-07-31 | Audrey Goddard | TIE ligand homologues |
CA2425145C (en) * | 2000-10-16 | 2011-08-30 | Genentech, Inc. | Methods of treatment using wisp polypeptides |
US20030027751A1 (en) * | 2001-04-10 | 2003-02-06 | Genvec, Inc. | VEGF fusion proteins |
US20030194798A1 (en) * | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
JP5105696B2 (ja) | 2001-11-16 | 2012-12-26 | ジェネンテック, インコーポレイテッド | アンジオポエチン様タンパク質3Angptl3含有組成物とその使用方法 |
JP4764630B2 (ja) * | 2002-09-09 | 2011-09-07 | ネクター セラピューティックス | 水溶性ポリマーアルカナール |
EP1860186B1 (en) * | 2003-03-10 | 2010-11-17 | Japan Science And Technology Agency | Method for distinguishing mesenchymal stem cells using different markers |
JP3979372B2 (ja) | 2003-09-26 | 2007-09-19 | ブラザー工業株式会社 | 画像処理装置、画像処理方法及び画像処理プログラム |
JP5269411B2 (ja) * | 2004-06-21 | 2013-08-21 | ザ クリーブランド クリニック ファウンデーション | 幹細胞をホーミングさせるためのccrリガンド |
AU2006223579A1 (en) | 2005-03-11 | 2006-09-21 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
JP5139271B2 (ja) | 2005-05-24 | 2013-02-06 | ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ | 培養した造血幹細胞を拡大しかつ分析する方法 |
US7601501B2 (en) * | 2006-08-11 | 2009-10-13 | The Scripps Research Institute | Controlling osteogenesis by inhibition of osteogenic suppressors |
WO2008137641A2 (en) | 2007-05-04 | 2008-11-13 | Whitehead Institute For Biomedical Research | Ex vivo expansion of human hematopoietic stem cells |
US20090104210A1 (en) | 2007-10-17 | 2009-04-23 | Tota Michael R | Peptide compounds for treating obesity and insulin resistance |
KR20160015403A (ko) * | 2009-07-14 | 2016-02-12 | 더 스크립스 리서치 인스티튜트 | 중간엽 줄기 세포 분화 |
UY35368A (es) | 2013-03-08 | 2014-10-31 | Irm Llc | Péptidos y composiciones para el tratamiento de daño articular |
MA38369B1 (fr) | 2013-03-08 | 2018-10-31 | Novartis Ag | Peptides et compositions pour le traitement d'une lesion de l'articulation |
-
2010
- 2010-07-13 KR KR1020167002298A patent/KR20160015403A/ko not_active Application Discontinuation
- 2010-07-13 EA EA201200118A patent/EA023073B1/ru not_active IP Right Cessation
- 2010-07-13 ES ES10800425.0T patent/ES2541217T3/es active Active
- 2010-07-13 KR KR1020177036199A patent/KR20180000337A/ko not_active Application Discontinuation
- 2010-07-13 NZ NZ597306A patent/NZ597306A/en not_active IP Right Cessation
- 2010-07-13 PE PE2012000052A patent/PE20120570A1/es not_active Application Discontinuation
- 2010-07-13 KR KR1020127001013A patent/KR101590834B1/ko active Application Filing
- 2010-07-13 CN CN201610077451.4A patent/CN105601728B/zh active Active
- 2010-07-13 IN IN572DEN2012 patent/IN2012DN00572A/en unknown
- 2010-07-13 BR BR112012000914A patent/BR112012000914B8/pt not_active IP Right Cessation
- 2010-07-13 PL PL10800425T patent/PL2453921T3/pl unknown
- 2010-07-13 MX MX2012000707A patent/MX2012000707A/es active IP Right Grant
- 2010-07-13 SG SG2011095148A patent/SG177318A1/en unknown
- 2010-07-13 CA CA2767826A patent/CA2767826C/en active Active
- 2010-07-13 AU AU2010273570A patent/AU2010273570B2/en not_active Ceased
- 2010-07-13 JP JP2012520725A patent/JP5602850B2/ja active Active
- 2010-07-13 PE PE2015002636A patent/PE20160507A1/es not_active Application Discontinuation
- 2010-07-13 EP EP10800425.0A patent/EP2453921B1/en active Active
- 2010-07-13 UA UAA201200493A patent/UA104031C2/uk unknown
- 2010-07-13 MY MYPI2011006173A patent/MY160951A/en unknown
- 2010-07-13 MA MA34524A patent/MA33423B1/fr unknown
- 2010-07-13 CN CN201080031985.4A patent/CN102625830B/zh active Active
- 2010-07-13 WO PCT/US2010/041850 patent/WO2011008773A2/en active Application Filing
- 2010-07-13 PT PT108004250T patent/PT2453921E/pt unknown
- 2010-07-13 US US13/383,962 patent/US9139633B2/en active Active
-
2011
- 2011-12-21 TN TNP2011000655A patent/TN2011000655A1/en unknown
-
2012
- 2012-01-05 IL IL217383A patent/IL217383A/en active IP Right Grant
- 2012-01-05 ZA ZA2012/00078A patent/ZA201200078B/en unknown
- 2012-01-12 CL CL2012000091A patent/CL2012000091A1/es unknown
- 2012-01-13 EC ECSP12011604 patent/ECSP12011604A/es unknown
- 2012-01-16 CU CU2012000007A patent/CU24042B1/es active IP Right Grant
- 2012-01-16 CR CR20120024A patent/CR20120024A/es unknown
- 2012-01-19 CO CO12007861A patent/CO6491059A2/es unknown
- 2012-02-09 GT GT201200011A patent/GT201200011A/es unknown
- 2012-05-28 HK HK12105181.4A patent/HK1164169A1/xx not_active IP Right Cessation
-
2015
- 2015-09-18 US US14/859,126 patent/US10064918B2/en active Active
-
2016
- 2016-08-17 IL IL247310A patent/IL247310B/en active IP Right Grant
-
2018
- 2018-08-21 US US16/106,893 patent/US10555990B2/en active Active
-
2019
- 2019-12-20 US US16/723,424 patent/US11241482B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU24042B1 (es) | Método para la inducción de diferenciación de células madre mesenquimales | |
CL2012002627A1 (es) | Metodos para aumentar la tolerancia al estres abiotico y/o reducir las consecuencias del estres abiotico en plantas que comprende ponerla en contacto con una composicion que contiene acido dicarboxilico o un derivado. | |
MX2012001310A (es) | Metodos para proporcionar efectos beneficos en la cavidad bucal. | |
BR112014010433A2 (pt) | método e máquina para produzir uma cápsula de uso único para bebidas e cápsula obtida com o método | |
CL2013003792A1 (es) | Metodo para detener el crecimiento celular en un cultivo celular de mamíferos que expresan una proteina recombinante. | |
CL2013003146A1 (es) | Formulación estable que comprende anticuerpo anti alfa 4 beta 7 y al menos un aminoacido libre; metodo para preparar la formulación; uso para tratar enfermedad inflamatoria. | |
AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
CL2014000759A1 (es) | Composicion para uso en el crecimiento del cerebro y/o desarrollo cognitivo y/o desarrollo psicomotor que comprende al menos un ácido graso poliinsaturado de cadena larga (lc-pufa), al menos un probiótico y una mezcla de oligosacáridos; uso de la composición. | |
CL2012003075A1 (es) | Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion. | |
NI201200029A (es) | Compuestos y composiciones como inhibidores de cinasa de proteína | |
BR112013004614A2 (pt) | Diferenciação de células-tronco pluripotentes | |
BR112012023537A2 (pt) | geração de progenitores mesenquimais clonais e linhagens de células tronco mesenquimais sob condições livres de soro. | |
BR112015030918A2 (pt) | método para produção de células progenitoras renais, e fármacos contendo células progenitoras renais | |
AR088920A1 (es) | Purificacion de anticuerpos anti-c-met | |
BR112016008576A2 (pt) | Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária | |
CL2013000580A1 (es) | Metodo de regeneracion o reparacion muscular que comprende administrar un antagonista del receptor de acido retinoico gama (rary); metodo para la induccion o estimulacion de diferenciacion miogenica de celulas madre; composicion que comprende celulas madre mesenquimales; composicion farmaceutica; kit. | |
WO2012141971A3 (en) | Methods and compositions for rejuvenation and expansion of stem cells | |
BR112013025777A2 (pt) | imidazopiridazinas como inibidores da quinase akt | |
CL2013001129A1 (es) | Composicion que comprende una celula madre gbm6-ad de glioblastoma purificada; metodo de generacion de anticuerpos especificos para gbm6-ad; dicho anticuerpo; metodo para producir una vacuna de celulas dendriticas; y su uso para el tratamiento de cancer. | |
ECSP11011076A (es) | Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma | |
WO2012095743A3 (en) | Adipose -derived mesenchymal stem cells for intralymphatic administration in autoimmune and inflammatory diseases | |
CL2016000746A1 (es) | Un método para producir un l-aminoácido usando una bacteria de la familia de las enterobacteriaceae teniendo atenuada la expresión de un gen que codifica un transportador de fosfato | |
BR112017008033A2 (pt) | composição farmacêutica para administração oral e respectivo processo de preparação | |
WO2014140362A3 (en) | Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(msc) | |
CL2013002006A1 (es) | Composicion farmaceutica que comprende un anticuerpo aislado que se une especificamente al factor de celulas madres; metodo de produccion del anticuerpo; y su uso para tratar o prevenir una enfermedad de remodelacion tisular o fibrotica en un sujeto. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant of patent |